WO2000069424A3 - Method of treating psychotic disorders - Google Patents

Method of treating psychotic disorders Download PDF

Info

Publication number
WO2000069424A3
WO2000069424A3 PCT/EP2000/003506 EP0003506W WO0069424A3 WO 2000069424 A3 WO2000069424 A3 WO 2000069424A3 EP 0003506 W EP0003506 W EP 0003506W WO 0069424 A3 WO0069424 A3 WO 0069424A3
Authority
WO
WIPO (PCT)
Prior art keywords
psychotic disorders
treating psychotic
activity
relates
treating
Prior art date
Application number
PCT/EP2000/003506
Other languages
French (fr)
Other versions
WO2000069424A2 (en
Inventor
Hes Roelof Van
Der Heijden Johannes A M Van
Cornelis G Kruse
Stephen K Long
Original Assignee
Solvay Pharm Bv
Hes Roelof Van
Heijden Johannes A M V D
Cornelis G Kruse
Stephen K Long
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv, Hes Roelof Van, Heijden Johannes A M V D, Cornelis G Kruse, Stephen K Long filed Critical Solvay Pharm Bv
Priority to AU45522/00A priority Critical patent/AU4552200A/en
Priority to JP2000617883A priority patent/JP2002544223A/en
Priority to EP00926982A priority patent/EP1200072A2/en
Priority to CA002373855A priority patent/CA2373855A1/en
Publication of WO2000069424A2 publication Critical patent/WO2000069424A2/en
Publication of WO2000069424A3 publication Critical patent/WO2000069424A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to the use of compounds having both dopamine D2-antagonistic activity and serotonin reuptake inhibitory (SRI) activity for the treatment of psychotic disorders such as schizophrenia. The invention further relates to a group of novel (1, 2, 3,6-tetrahydropyridin-4-yl) indole and -furan derivatives having these activities.
PCT/EP2000/003506 1999-05-12 2000-04-14 Method of treating psychotic disorders WO2000069424A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU45522/00A AU4552200A (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders
JP2000617883A JP2002544223A (en) 1999-05-12 2000-04-14 How to treat psychotic disorders
EP00926982A EP1200072A2 (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders
CA002373855A CA2373855A1 (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201524.8 1999-05-12
EP99201524 1999-05-12

Publications (2)

Publication Number Publication Date
WO2000069424A2 WO2000069424A2 (en) 2000-11-23
WO2000069424A3 true WO2000069424A3 (en) 2001-06-07

Family

ID=8240207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003506 WO2000069424A2 (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders

Country Status (5)

Country Link
EP (1) EP1200072A2 (en)
JP (1) JP2002544223A (en)
AU (1) AU4552200A (en)
CA (1) CA2373855A1 (en)
WO (1) WO2000069424A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028685A1 (en) * 2000-06-14 2003-05-21 Lundbeck & Co As H INDOL DERIVATIVES
DE102004023635A1 (en) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroaryl-substituted cyclohexyl-1,4-diamine derivatives
DE102004023632A1 (en) * 2004-05-10 2005-12-08 Grünenthal GmbH Substituted cyclohexylcarboxylic acid derivatives
DE102004023522A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituted cyclohexyl-1,4-diamine derivatives
DE102004023507A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituted cyclohexylacetic acid derivatives
DE102004023501A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Oxo-substituted cyclohexyl-1,4-diamine derivatives
DE102004023506A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Chain-extended substituted cyclohexyl-1,4-diamine derivatives
DE102004023508A1 (en) * 2004-05-10 2005-12-08 Grünenthal GmbH Acid derivatives of substituted cyclohexyl-1,4-diamine
DE602005016836D1 (en) * 2004-11-26 2009-11-05 Janssen Pharmaceutica Nv CHOTIC AND ANXIOLYTIC ACTIVITY
US7371769B2 (en) 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
KR20070091009A (en) * 2004-12-07 2007-09-06 솔베이 파마슈티칼스 비. 브이 Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
US20070072870A2 (en) 2004-12-08 2007-03-29 Solvay Pharmeceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012977A1 (en) * 1991-01-28 1992-08-06 Warner-Lambert Company Substituted indoles as central nervous system agents
EP0560669A1 (en) * 1992-03-11 1993-09-15 Bristol-Myers Squibb Company Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes
DE4414113A1 (en) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-indolylpiperidines
EP0722942A1 (en) * 1995-01-12 1996-07-24 MERCK PATENT GmbH Indole piperidine derivatives
WO1997017343A1 (en) * 1995-11-06 1997-05-15 American Home Products Corporation Indolealkyl derivatives of benzodioxanmethylamine as 5-ht1a receptor ligands
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses
WO1998028293A1 (en) * 1996-12-20 1998-07-02 H.Lundbeck A/S Indane or dihydroindole derivatives
WO2000023441A1 (en) * 1998-10-16 2000-04-27 Duphar International Research Bv 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012977A1 (en) * 1991-01-28 1992-08-06 Warner-Lambert Company Substituted indoles as central nervous system agents
EP0560669A1 (en) * 1992-03-11 1993-09-15 Bristol-Myers Squibb Company Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes
DE4414113A1 (en) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-indolylpiperidines
EP0722942A1 (en) * 1995-01-12 1996-07-24 MERCK PATENT GmbH Indole piperidine derivatives
WO1997017343A1 (en) * 1995-11-06 1997-05-15 American Home Products Corporation Indolealkyl derivatives of benzodioxanmethylamine as 5-ht1a receptor ligands
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses
WO1998028293A1 (en) * 1996-12-20 1998-07-02 H.Lundbeck A/S Indane or dihydroindole derivatives
WO2000023441A1 (en) * 1998-10-16 2000-04-27 Duphar International Research Bv 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G.D. BARTOSZYK ET AL.: "EMD 86006: A SEROTONIN (5-HT) REUPTAKE INHIBITOR AND DOPAMIN DA-D2 ANTAGONIST", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, pages 1112, XP000869625 *
R. DAVIS ET AL.: "Ziprasidone", CNS DRUG, vol. 8, no. 2, 1997, pages 153 - 162, XP002127987 *

Also Published As

Publication number Publication date
CA2373855A1 (en) 2000-11-23
JP2002544223A (en) 2002-12-24
EP1200072A2 (en) 2002-05-02
AU4552200A (en) 2000-12-05
WO2000069424A2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
PL377587A1 (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
IL175819A0 (en) Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
MY133238A (en) Monoamine reuptake inhibitors for treatment for cns disorders
YU21702A (en) Substituted indoles for modulating nfkb activity
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
NO20044501L (en) [1,4] diazenino [6,7,1-IJ] quinoline derivatives such as antipsychotics and antidepressants
MX9602517A (en) Naphthylamides as central nervous system agents.
WO2000069424A3 (en) Method of treating psychotic disorders
AU7538200A (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
UA72948C2 (en) Substituted derivatives of phenylpiperazine, a pharmaceutical composition and a method for treatment of affective or neurologic diseases and disorders
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
IL172134A0 (en) Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
WO2001007431A3 (en) Benzothiophene derivatives
WO2001034548A3 (en) 3-heteroatom substituted and two carbon homologs of 15-hete and methods of use
AU2003213896A1 (en) Process to obtain dibenzylbutyrolactonic lignans; process to obtain synthetic derivatives from lignanes bearing anti-chagas chemoprophylactic and therapeutical activities
WO2001023385A3 (en) Novel tropane analogs
NO20035642D0 (en) Process for the preparation of derivatives of 1,5-diaryl-3-trifluoromethyl-delta-2-pyrazolines which are racemically and enantiomerically pure
MXPA05009763A (en) 2-(butyl-1 -sulfonylamino) -n-[1(r) -(6-methoxy -pyridin -3-yl)- propyl] -benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound.
AU6385200A (en) Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
WO2002046163A3 (en) Quinoline derivatives and their use as anti-epileptics
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 617883

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2373855

Country of ref document: CA

Ref country code: CA

Ref document number: 2373855

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000926982

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000926982

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09959933

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000926982

Country of ref document: EP